<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914159</url>
  </required_header>
  <id_info>
    <org_study_id>N-037.0156</org_study_id>
    <nct_id>NCT01914159</nct_id>
  </id_info>
  <brief_title>Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study</brief_title>
  <acronym>RIP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration
      (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical
      trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab
      (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study
      period of 12 months in 30 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Morphology</measure>
    <time_frame>12 months</time_frame>
    <description>Spectral-domain optical coherence tomography (SD-OCT) central retinal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision-related Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>National Eye Institute Visual Function Questionaire 25-item version (NEI VFQ-25)
0 to 100 scale, where 100 represents the best possible score and 0 represents the worst
Reference: Mangione CM et al. Arch Ophthalmol 2001 Jul;119(7):1050-8.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)</intervention_name>
    <description>Monthly intravitreal injections</description>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a pigment epithelial tear secondary to age-related macular degeneration

          -  Written informed consent

        Exclusion Criteria:

          -  Time of diagnosis more than 6 months before study recruitment

          -  Ocular surgery of the study eye within 1 month before study recruitment

          -  Extensive subretinal fibrosis or retinal atrophy of the study eye

          -  Significant opacification of optical media of the study eye

          -  Uncontrolled glaucoma of the study eye

          -  Active ocular inflammation of the study eye

          -  Best-corrected visual acuity of the contralateral eye below 20/200

          -  Concurrent ocular or systemic therapy with other vascular endothelial growth factor
             (VEGF)-inhibitory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Bonn, Department of Ophthalmology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of München (LMU), Department of Ophthalmology</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universityof Münster, Department of Ophthalmology</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 28, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2019</results_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank G. Holz</investigator_full_name>
    <investigator_title>Director, Department of Ophthalmology, University of Bonn</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best-corrected visual acuity</title>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central retinal thickness</title>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="571" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vision-related quality of life</title>
          <description>National Eye Institute Visual Function Questionaire 25-item version (NEI VFQ-25)
0 to 100 scale, where 100 represents the best possible score and 0 represents the worst
Reference: Mangione CM et al. Arch Ophthalmol 2001 Jul;119(7):1050-8.</description>
          <units>NEI VFQ-25 score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.0" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best-corrected Visual Acuity</title>
        <description>Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
          </group>
        </group_list>
        <measure>
          <title>Best-corrected Visual Acuity</title>
          <description>Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol</description>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Morphology</title>
        <description>Spectral-domain optical coherence tomography (SD-OCT) central retinal thickness</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Morphology</title>
          <description>Spectral-domain optical coherence tomography (SD-OCT) central retinal thickness</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision-related Quality of Life</title>
        <description>National Eye Institute Visual Function Questionaire 25-item version (NEI VFQ-25)
0 to 100 scale, where 100 represents the best possible score and 0 represents the worst
Reference: Mangione CM et al. Arch Ophthalmol 2001 Jul;119(7):1050-8.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
          </group>
        </group_list>
        <measure>
          <title>Vision-related Quality of Life</title>
          <description>National Eye Institute Visual Function Questionaire 25-item version (NEI VFQ-25)
0 to 100 scale, where 100 represents the best possible score and 0 represents the worst
Reference: Mangione CM et al. Arch Ophthalmol 2001 Jul;119(7):1050-8.</description>
          <units>NEI VFQ-25 score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab</title>
          <description>Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany): Monthly intravitreal injections</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increase of subretinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tim U. Krohne, MD, FEBO</name_or_title>
      <organization>Dept of Ophthalmology, University of Bonn, Bonn, Germany</organization>
      <phone>+49 228 287 ext 15505</phone>
      <email>krohne@uni-bonn.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

